{"id":553,"date":"2023-06-12T14:24:00","date_gmt":"2023-06-12T14:24:00","guid":{"rendered":"https:\/\/accesscg.org\/front-germany\/"},"modified":"2026-04-07T17:55:57","modified_gmt":"2026-04-07T17:55:57","slug":"front-germany","status":"publish","type":"page","link":"https:\/\/accesscg.org\/en-sp\/","title":{"rendered":"Front (Spain)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||13px|||&#8221; custom_padding=&#8221;17px||0px|||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; positioning=&#8221;none&#8221; position_origin_a=&#8221;top_right&#8221; position_origin_r=&#8221;bottom_left&#8221; custom_css_main_element=&#8221;||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2 style=\"text-align: left;\">ACCESS Consensus Group expert report urges action to improve cervical cancer screening participation and equity across Spain<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p style=\"text-align: center;\">RECOMMENDATIONS ON CERVICAL CANCER SCREENING IN SPAIN<em>Expert views from different autonomous communities<\/em><\/p>\n<p>Cervical cancer remains a preventable yet persistent health burden in Spain despite scientific and technological advances. In response to declines in cervical cancer screening uptake across high-income countries, the ACCESS International Consensus Group developed the \u201c<a href=\"https:\/\/accesscg.org\/wp-content\/uploads\/2023\/07\/ACCESS-CG_White-Paper.pdf\"><em>Turning the Tide<\/em><\/a><em>\u201d<\/em> White Paper, which outlines six key recommendations to improve screening participation, equity, and accessibility. A new exploratory analysis in Spain led by leading experts in the field was undertaken to identify good practices that can serve as examples for other regions and pinpoint policy gaps hindering implementation of the six recommendations. The analysis includes a RAG (red\/amber\/green) rating model to reflect current implementation levels and help prioritise areas for improvement.<\/p>\n<p><span style=\"color: #e09900;\"><strong>Key recommendations include:\u00a0<\/strong><\/span><\/p>\n<p><strong>National level:<\/strong><\/p>\n<ol>\n<li>Strengthen the Ministry of Health\u2019s strategic role via an ambitious, coordinated roadmap for screening implementation, with defined timelines, targets exceeding WHO minimums, and an equity-centred approach.<\/li>\n<li>Improve equity and data quality through standardised systems that enable comparable monitoring of invitations, participation, follow-up, and outcomes across regions, age groups, and vulnerable populations.<\/li>\n<li>Standardise and link key registries\u2014including population, cancer, primary care, screening, and vaccination\u2014to assess territorial inequities, ensure interoperability and enable comprehensive, data-driven decisions.<\/li>\n<li>Promote culturally adapted national information and awareness campaigns targeted at under-screened women, coordinating traditional, digital, and community channels with regional health services.<\/li>\n<li>Integrate economic evaluation into the national indicator framework, promoting cost-effectiveness analyses that compare screening strategies to inform investment decisions and assess health and budget impacts.<\/li>\n<li>Promote partnerships with key social stakeholders\u2014such as patient groups, community organizations, and women\u2019s health entities\u2014by implementing funding mechanisms, technical support, and educational campaigns to boost screening uptake and address cultural and social barriers.<\/li>\n<li>Create permanent mechanisms for interregional learning to enable systematic exchange of experiences, best practices, and lessons learned, to reduce implementation gaps and increase screening uptake across the country.<\/li>\n<li>Strengthen multilevel coordination by aligning efforts between the Ministry of Health, regional health services, and civil society stakeholders to reduce implementation disparities and ensure nationwide coverage.<\/li>\n<li>Mobilise European and national resources, prioritising allocation to autonomous communities facing greater technical and institutional challenges, in order to accelerate the rollout of population-based screening and promote innovative measures.<\/li>\n<\/ol>\n<p><strong>Regional Level:<\/strong><\/p>\n<ol>\n<li>Align regional plans with the national framework, including coverage targets, quality standards, and equity priorities, with the Ministry of Health\u2019s technical support where operational or budgetary constraints exist.<\/li>\n<li>Deploy effective accessibility strategies, especially in regions with lower screening coverage, prioritising optimised invitation systems (SMS, mail, and digital channels), extended screening appointments, and offering screening in settings beyond primary healthcare centres.<\/li>\n<li>Consider the gradual implementation of HPV self-sampling an additional tool to improve screening participation, ensuring its deployment is subject to evaluation, appropriate mechanisms for quality control and traceability. Implementation should be progressive and evaluated, ensuring device validation, analysis of screening coverage and outcomes, traceability of samples, and the existence of clear clinical follow-up protocols.<\/li>\n<li>Incorporate economic evaluation into the design and monitoring of screening programmes, considering cost-effectiveness analyses, selection of the primary test, screening intervals, and follow-up strategies. This approach would help optimise resources, support evidence-based decision-making, and strengthen the long-term sustainability of the programme.<\/li>\n<li>Ensure continuous training and support for healthcare professionals, providing tools to strengthen communication with under-screened women. Explore non-financial incentives such as harmonised criteria for professional accreditation, institutional recognition, or including screening promotion in performance evaluation systems.<\/li>\n<li>Strengthen technical coordination between regional health services and scientific societies to harmonise quality standards, training, and professional accreditation in cervical cancer screening and follow-up.<\/li>\n<\/ol>\n<p><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\"><\/span><\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/accesscg.org\/wp-content\/uploads\/2026\/04\/ACCESS_RECOMENDACIONES-SOBRE-EL-CRIBADO-DE-CANCER-DE-CUELLO-UTERINO-EN-ESPANA.pdf&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;READ THE FULL REPORT (SPANISH)&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;14px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#06c8ff&#8221; button_border_width=&#8221;10px&#8221; button_border_color=&#8221;#06c8ff&#8221; button_border_radius=&#8221;100px&#8221; button_letter_spacing=&#8221;3px&#8221; button_font=&#8221;Roboto|700||on|||||&#8221; custom_margin=&#8221;2em||2em||true|false&#8221; custom_padding=&#8221;0.3em|14px|0.3em|14px|false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; module_alignment=&#8221;center&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; positioning=&#8221;none&#8221; position_origin_a=&#8221;top_right&#8221; position_origin_r=&#8221;bottom_left&#8221; custom_css_main_element=&#8221;||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h2 style=\"text-align: left;\"><span style=\"color: #e09900;\">Project Team<\/span><\/h2>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; min_height=&#8221;117.1px&#8221; custom_padding=&#8221;5px|||||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; min_height=&#8221;57.5px&#8221; custom_padding=&#8221;7px|||||&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; custom_margin=&#8221;||18px||false|false&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>National Expert Group<\/strong> \u2013 provided both regional and national perspectives<\/p>\n<p><em>Project Coordinators \u2013 ACCESS members responsible for overseeing the project methodology in Spain and ensuring alignment of the analysis with the study objectives<\/em><\/p>\n<ul>\n<li><strong>Dr Rosario Granados<\/strong>, Head of the Pathology Department at Hospital Universitario de Getafe (Madrid Regional Health Service), Former President of the European Federation of Cytology Societies and of the Spanish Society of Cytology, Spain. Member, ACCESS Consensus Group<\/li>\n<li><strong>Dr Xavier Bosch<\/strong>, Clinical oncologist and epidemiologist, co-founder of the HPV Information Centre (ICO and IARC), Director of HPV World (HPW), Spain. Member, ACCESS Consensus Group<\/li>\n<\/ul>\n<p><em>Report Contributors \u2013 provided technical and context-specific insights on the implementation of screening programmes in participating regions, and contributed to the report review through comments and observations<\/em><\/p>\n<p><em><\/em><\/p>\n<ul>\n<li><strong>Dr Elena Bartolom\u00e9<\/strong>, Head of Cancer Screening Programs at the Regional Office for Oncology Coordination, Community of Madrid. Board Member, Spanish Society for Healthcare Quality<\/li>\n<li><strong>Dr Elena Rodr\u00edguez Camacho<\/strong>, MD, PhD, Specialist in Preventive Medicine and Public Health, Technical Officer at the Early Disease Detection Service of the Directorate-General of Public Health, Ministry of Health, Xunta de Galicia<\/li>\n<li><strong>Dr Mar\u00eda Jos\u00e9 Mac\u00edas<\/strong>, Head of Health Promotion and Disease Prevention Programmes at the Directorate-General for Public Health, Extremadura Health Service (SES), Spain<\/li>\n<li><strong>Dr Marta del Pino<\/strong>, Consultant at the Gynecologic Oncology Unit, Hospital Cl\u00ednic de Barcelona, and Associate Professor of Medicine at the University of Barcelona<\/li>\n<\/ul>\n<p><em>Other Contributors <\/em>\u2013 <em>provided data specific to their respective regional screening programmes<\/em><span style=\"font-size: 18px;\">\u00a0<\/span><\/p>\n<ul>\n<li><strong>David del Valle Pe\u00f1a<\/strong>, Cervical Cancer Early Detection Screening Program, Osakidetza. Gynecologist at the Cervical Pathology Unit, Donostia University Hospital.<\/li>\n<li><strong>Generalitat Valenciana (Regional Government of Valencia)<\/strong>, Screening Programs Service, Deputy Directorate-General for Health Promotion and Prevention, Directorate-General for Public Health<strong style=\"font-size: 18px;\">\u00a0<\/strong><\/li>\n<\/ul>\n<p><strong>International Steering Group <\/strong>\u2013 led the overall methodological design and strategy of the RAG report project to their respective regional screening programmes<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.21.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<ul>\n<li><strong>Dr Mairead O\u2019Connor<\/strong>, Research Officer, National Screening Service Ireland, behavioural scientist, Member, ACCESS Consensus Group, Ireland<\/li>\n<li><strong style=\"font-size: 18px;\">Philippe Descamps<\/strong><span style=\"font-size: 18px;\">, Professor and Head of the Department of Obstetrics and Gynecology, Angers University Hospital. Former Vice-President of the International Federation of Gynecology and Obstetrics (FIGO), Co-chair, ACCESS Consensus Group<\/span><\/li>\n<li><strong>Dr Rosario Granados<\/strong>, Head of the Pathology Department at Hospital Universitario de Getafe (Madrid Regional Health Service), Former President of the European Federation of Cytology Societies and of the Spanish Society of Cytology, Spain. Member, ACCESS Consensus Group<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ACCESS Consensus Group expert report urges action to improve cervical cancer screening participation and equity across SpainRECOMMENDATIONS ON CERVICAL CANCER SCREENING IN SPAINExpert views from different autonomous communities Cervical cancer remains a preventable yet persistent health burden in Spain despite scientific and technological advances. In response to declines in cervical cancer screening uptake across high-income [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder -->\n[et_pb_section fb_built=\"1\" _builder_version=\"4.21.0\" _module_preset=\"default\" module_alignment=\"center\" custom_margin=\"||13px|||\" custom_padding=\"17px||0px|||\" global_colors_info=\"{}\"][et_pb_row _builder_version=\"4.21.0\" _module_preset=\"default\" module_alignment=\"center\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.21.0\" _module_preset=\"default\" positioning=\"none\" position_origin_a=\"top_right\" position_origin_r=\"bottom_left\" custom_css_main_element=\"||\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"]<h2 style=\"text-align: left;\">ACCESS Consensus Group and ZERVITA e.V. convene experts in Germany to elaborate recommendations for a future national strategy for the elimination of HPV-related cancers<\/h2>[\/et_pb_text][et_pb_image src=\"https:\/\/accesscg.org\/wp-content\/uploads\/2025\/08\/ACCESS-Consensus-Group-and-ZERVITA-e.v-Germany-Roundtable-1.png\" title_text=\"ACCESS Consensus Group and ZERVITA e.v Germany Roundtable\" align=\"center\" _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.21.0\" _module_preset=\"default\" min_height=\"117.1px\" custom_padding=\"5px|||||\" global_colors_info=\"{}\"][et_pb_row _builder_version=\"4.21.0\" _module_preset=\"default\" min_height=\"57.5px\" custom_padding=\"7px|||||\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]<p>The elimination of HPV-related cancers is no longer a distant aspiration, but a realistic and achievable public health objective. These cancers are distinctive in that they result from a clearly identifiable and preventable cause. Unlike many other forms of cancer, an effective means of primary prevention exists in the form of HPV vaccination. Secondary prevention is also well-established through cervical cancer screening. Yet, despite these conditions, the two pillars of prevention \u2013 vaccination and screening \u2013 remain underutilised in Germany relative to what is both possible and necessary.<\/p>\n<p>Nationwide, the HPV vaccination rate among 15-year-old girls remains below 55%, and among boys, it stands at just 34%. As a result, Germany falls well short of the WHO target of vaccinating 90% of girls under the age of 15, and also lags significantly behind many other European countries. In addition, participation in cytology-based cervical cancer screening stood at only 45% among women under the age of 35 with statutory health insurance in 2021. Rates are even lower among certain high-risk populations, particularly socioeconomically disadvantaged groups, migrant women, and women with lower levels of education, who are especially underserved.<\/p>\n<p>On 23-24 July 2025, the ACCESS International Consensus Group on Cervical Cancer and ZERVITA e.V. co-organised an expert roundtable in Frankfurt. Chaired by Prof. Thomas Iftner, ACCESS member and Chair of ZERVITA e.V., the meeting convened 20 experts and key opinion leaders from across Germany, including gynaecologists, pathologists, paediatricians and patient representatives. The discussions focused on the urgent need for a national strategy to eliminate HPV-related cancers, with a particular emphasis on boosting HPV vaccination and cervical screening uptake.<\/p>\n<p>Presentations were delivered on the current state of HPV vaccination and cervical cancer screening in Germany, followed by insights into existing information, education and awareness-raising efforts. Perspectives from affected individuals and patient groups were shared, along with an in-depth examination of the barriers to participation in both vaccination and screening. Participants also explored strategies to raise HPV vaccination coverage and improve access to screening services.<\/p>\n<p>One of the key outcomes of the roundtable was the recognition that a holistic and unified strategy, integrating both HPV vaccination and cervical cancer screening, is crucial for reaching elimination, moving away from siloed approaches to a coordinated, strategic effort. The meeting further underscored the importance of strengthening collaboration among stakeholders and highlighted the vital roles of policymakers, health insurance providers, and civil society in driving progress toward the elimination goal. The need for sustained public education and continuous training for healthcare professionals was also emphasized as essential to effective cancer prevention.<\/p>\n<p>This meeting laid the foundation for the development of an expert consensus policy paper outlining key components of a future national strategy to eliminate HPV-related cancers in Germany. The paper is expected to be published by the end of 2025.<\/p>\n<p>&nbsp;<\/p>[\/et_pb_text][et_pb_image src=\"https:\/\/accesscg.org\/wp-content\/uploads\/2025\/08\/undefined-2-2-scaled.jpg\" title_text=\"undefined (2)\" align=\"center\" _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.21.0\" _module_preset=\"default\" custom_margin=\"-43px|||||\" custom_padding=\"0px|||||\" global_colors_info=\"{}\"][et_pb_row _builder_version=\"4.21.0\" _module_preset=\"default\" custom_padding=\"0px|||||\" global_colors_info=\"{}\"][et_pb_column type=\"4_4\" _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"]<p style=\"text-align: left;\"><span data-contrast=\"none\">Read ZERVITA e.V.\u2019s blog post on our joint roundtable <\/span><a href=\"https:\/\/zervita.de\/2025\/07\/25\/runder-tisch-zur-eliminierung-von-hpv-bedingtern-krebsarten-in-deutschland\/\"><span data-contrast=\"none\">here<\/span><\/a><span data-contrast=\"none\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>[\/et_pb_text][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"]<p style=\"text-align: left;\"><em><span data-contrast=\"none\" xml:lang=\"EN-US\" lang=\"EN-US\" class=\"TextRun SCXW87204417 BCX8\"><span class=\"NormalTextRun SCXW87204417 BCX8\" data-ccp-parastyle=\"Normal (Web)\">The ACCESS-ZERVITA expert roundtable was supported by Hologic and MSD Germany.<\/span><\/span><span class=\"EOP SCXW87204417 BCX8\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/em><\/p>[\/et_pb_text][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"]<p><span style=\"color: #004e8d;\"><strong>_______________<\/strong><\/span><\/p>\n<p><span style=\"color: #004e8d;\"><strong>ABOUT THE ACCESS CONSENSUS GROUP<\/strong><\/span><\/p>\n<p>The Advancing Cervical CancEr ScreeningS (ACCESS) International Consensus Group on Cervical Cancer is made up of professionals with a broad range of experience and expertise in women\u2019s health \u2014 focusing on cervical cancer from clinical, epidemiological, academic, patient, and advocacy perspectives. Together, we work to review the latest available evidence that supports optimal cervical cancer screening strategies in countries with organised cervical cancer screening programmes and make recommendations to relevant stakeholders and policymakers to advance women\u2019s health by increasing the uptake of screening amongst under-screened women.<\/p>[\/et_pb_text][et_pb_text _builder_version=\"4.21.0\" _module_preset=\"default\" global_colors_info=\"{}\"]<p><span style=\"color: #004e8d;\"><strong>_______________<\/strong><\/span><\/p>\n<p><span style=\"color: #004e8d;\"><strong>ABOUT ZERVITA<\/strong><\/span><\/p>\n<p><span data-contrast=\"none\" xml:lang=\"EN-GB\" lang=\"EN-GB\" class=\"TextRun SCXW69839600 BCX8\"><span class=\"NormalTextRun SCXW69839600 BCX8\">ZERVITA<\/span><span class=\"NormalTextRun SCXW69839600 BCX8\"> is a<\/span><span class=\"NormalTextRun SCXW69839600 BCX8\">n initiative <\/span><span class=\"NormalTextRun SCXW69839600 BCX8\">and <\/span><span class=\"NormalTextRun SCXW69839600 BCX8\">non<\/span><span class=\"NormalTextRun SCXW69839600 BCX8\">-profit association in Germany dedicated to raising awareness, promoting prevention, and fostering collaboration to combat HPV-related cancers. It focuses on public outreach and education for both the general population and professional audiences, advocating for vaccination, early detection, and the long-term goal of <\/span><span class=\"NormalTextRun SCXW69839600 BCX8\">eliminating<\/span><span class=\"NormalTextRun SCXW69839600 BCX8\"> HPV-related cancers in Germany.<\/span><\/span><span class=\"EOP SCXW69839600 BCX8\" data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" fullwidth=\"on\" _builder_version=\"4.21.0\" _module_preset=\"default\" min_height=\"126px\" custom_padding=\"121px|||||\" global_colors_info=\"{}\"][\/et_pb_section]\n<!-- \/wp:divi\/placeholder -->","_et_gb_content_width":"","footnotes":""},"class_list":["post-553","page","type-page","status-publish","hentry"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/pages\/553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/comments?post=553"}],"version-history":[{"count":0,"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/pages\/553\/revisions"}],"wp:attachment":[{"href":"https:\/\/accesscg.org\/en-sp\/wp-json\/wp\/v2\/media?parent=553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}